Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 13/20 | 0.58 |
| ▸ | NPC1 | O15118 | 12/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | MITF | O75030 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25142778 | 0.87 | SMN1; SMN2 (0.57) | RAB9ANPC1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL5534388 | 0.86 | GCK (0.54) | RAB9ANPC1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL31110024 | 0.86 | SMN1; SMN2 (0.56) | RAB9ANPC1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL25142712 | 0.85 | RAB9A (0.55) | RAB9ANPC1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL31665212 | 0.82 | RAB9A (0.55) | RAB9ANPC1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL25142518 | 0.82 | RAB9A (0.55) | RAB9ANPC1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL27134454 | 0.82 | RAB9A (0.60) | RAB9ANPC1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL31665552 | 0.82 | RAB9A (0.55) | RAB9ANPC1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL27134453 | 0.82 | RAB9A (0.59) | RAB9ANPC1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL25142631 | 0.81 | RAB9A (0.53) | RAB9ANPC1SMN1; SMN2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250235543-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2025-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250235543-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, TP53BP1 | RAB9A 3234/4885NPC1 3357/4885SMN1; SMN2 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.